Infosys’ Early Bet on Whoop Nears $100 Million as Wearable Giant Prepares for IPO
In the world of corporate venture capital, patience is often the most undervalued virtue. For Infosys, a $3 million investment made nearly a decade ago is now on the verge of delivering a spectacular return.
The Bengaluru-based IT services giant holds approximately a 1% stake in Whoop, the Boston-based maker of screenless fitness bands, which is now valued at nearly $100 million . This marks a staggering return on an investment that began in December 2015 under former CEO Vishal Sikka, when Infosys first backed the wearable startup .
Today, Whoop is one of the most valuable private companies in the health-tech space, with a $10.1 billion valuation following a $575 million Series G funding round in late March 2026 . The company is now actively preparing for an IPO within the next 18–24 months .
The Numbers: Whoop’s Explosive Growth
Whoop’s trajectory from a niche fitness tracker for elite athletes to a mainstream health platform has been nothing short of remarkable.
| Metric | Value |
|---|---|
| Current Valuation | $10.1 billion (after Series G) |
| Previous Valuation (2021) | $3.6 billion |
| Total Raised to Date | $950+ million |
| Infosys Stake Value | ~$100 million |
| Infosys Initial Investment | $3 million (2015) |
| Global Members | 2.5 million+ |
| 2025 Bookings Growth | 103% year-over-year |
| 2025 Revenue Run Rate | $1.1 billion |
| Cash Flow | Positive in 2025 |
| Planned New Hires (2026) | 600+ roles |
| Target IPO Timeline | 18–24 months |
The company’s bookings more than doubled in 2025, finishing the year at a $1.1 billion revenue run rate, while turning cash flow positive for the first time . It currently operates in 60 countries, with 60% of sales now coming from outside the United States—a dramatic shift from just four years ago when the US made up about 70% of its member base .
The Vision: From Fitness Tracker to Health Operating System
Whoop founder and CEO Will Ahmed has a far more ambitious vision than simply counting steps or tracking sleep. He envisions Whoop evolving into a “health operating system” using its own artificial intelligence models to analyze health data continuously .
The platform is powered by more than 24 billion hours of physiological data and purpose-built AI models to provide predictive, personalized health insights . It claims to help users understand how they slept, whether they have recovered, how hard to push or pull back, and how daily behaviors like training, nutrition, and stress are impacting their long-term health .
Ahmed has set an even more ambitious goal: using Whoop’s AI to one day be able to predict heart attacks, strokes, and other serious health conditions before they occur . This vision aligns with a broader industry shift from reactive healthcare to proactive, preventive health management.
Key Features of Whoop’s Platform:
- Screenless wearable design that focuses entirely on data collection and analysis
- Subscription-based model (the wearable itself is free; members pay for insights)
- Continuous monitoring of heart rate, HRV, respiratory rate, skin temperature, blood oxygen, and (subject to regulatory negotiation) blood pressure
- AI-powered insights that provide daily recommendations on strain, recovery, and sleep
Regulatory Navigation: The FDA Challenge
Whoop’s journey has not been without obstacles. In July 2025, the US Food and Drug Administration (FDA) issued a warning letter to Whoop regarding its Blood Pressure Insights (BPI) feature . The agency claimed that BPI qualified as a medical device because it was “intended for use in the diagnosis of disease or other conditions,” and therefore required clearance or approval .
Whoop respectfully disagreed, maintaining that Blood Pressure Insights is a wellness feature, not a medical device, designed to help users understand how their body responds to daily life rather than to diagnose or treat any condition .
The regulatory landscape has since shifted in Whoop’s favor. In January 2026, the FDA announced plans to limit regulations on wearable medical devices, taking an even more limited regulatory approach towards companies like Whoop, Apple, Fitbit, and Oura . This move is being classified as a pivotal moment for digital health that will clear the field for new developments.
As Oura CEO Tom Hale noted on LinkedIn: “We’ve been vocal about our support of this type of distinction at the regulatory level… It’s our belief that wearable features that show trends, ranges, and changes over time can responsibly support wellbeing without serving as diagnostic tools” .
The Investor Lineup: Athletes, Institutions, and Infosys
Whoop’s Series G round in March 2026 was led by Collaborative Fund, with participation from a stellar lineup of institutional and individual investors :
Institutional Investors:
- Qatar Investment Authority
- Mubadala Investment Co.
- Abbott Laboratories (healthcare giant)
- Mayo Clinic
- 2PointZero Group
- GP Bullhound
Individual Investors:
- Cristiano Ronaldo (football icon)
- LeBron James (NBA superstar)
- Rory McIlroy (golf champion)
- Reggie Miller (NBA legend)
- Niall Horan (musician)
The presence of healthcare giant Abbott and the Mayo Clinic is particularly notable, signaling that the medical establishment is taking wearable health technology seriously as a tool for preventive care .
Infosys’ Strategic Bet: Beyond the Financial Return
For Infosys, the Whoop investment represents more than just a financial windfall. It reflects a broader strategic intent during the Vishal Sikka era to move beyond traditional IT services and make strategic bets on digital platforms and emerging ecosystems .
Phil Fersht, CEO of HFS Research, captured this well: *”What’s notable is not just the financial upside, but the strategic intent. A $3 million investment translating into exposure to a multibillion-dollar company shows services firms can create real enterprise value by embedding themselves in platform growth stories”* .
However, he also added a note of caution: “One success does not make a venture strategy. The opportunity lies in turning these into a repeatable growth engine aligned with AI-led services transformation” .
Peter Bendor-Samuel, founder and executive chairman of Everest Group, offered a more tempered perspective: “Such windfalls are unlikely to materially move Infosys’ stock. Strategically, it makes more sense to invest in startups that could disrupt tech services. The real test is whether these bets shape Infosys’ long-term growth trajectory” .
What This Means for India’s Corporate Venture Ecosystem
Whoop’s success carries several important signals for Indian corporates and the startup ecosystem:
1. Corporate Venture Capital Can Deliver Outsized Returns
The 33x return on Infosys’ initial investment (from $3 million to $100 million) demonstrates that Indian corporates can generate significant value by backing disruptive startups early, even in global markets.
2. Health-Tech Wearables Are a Massive Growth Market
Whoop’s 103% bookings growth and $1.1 billion revenue run rate reflect surging global demand for continuous health monitoring. This sector is poised for continued expansion as consumers take greater ownership of their health data.
3. The Lines Between Wellness and Medical Devices Are Blurring
The FDA’s evolving stance on wearables suggests that regulatory clarity is emerging, potentially opening new markets for health-tech startups that can navigate the approval process.
4. Indian IT Services Firms Can Diversify Beyond Traditional Revenue
Infosys’ successful bet on Whoop shows that Indian IT companies can use their cash reserves and innovation funds to build exposure to high-growth platform businesses, diversifying away from pure-play services revenue.
The Road Ahead: Whoop’s IPO and Beyond
Whoop is actively preparing for a public listing within the next 18 to 24 months . The company is in the midst of a significant hiring spree, planning to expand its staff by as much as 75% in 2026, adding more than 600 new roles across software, research, design, hardware, product development, manufacturing, sales, and marketing .
International expansion remains a key priority. Whoop currently operates in 60 countries, with 60% of sales coming from outside the US. The Series G funding will fuel further growth across Europe, the GCC, Latin America, and Asia .
For Infosys, the eventual IPO will provide a clear path to liquidity for its nearly $100 million stake. Whether the company chooses to hold or sell will be closely watched by investors tracking the performance of its innovation fund.
The Final Word
Infosys’ early bet on Whoop is a masterclass in patient, strategic corporate venture capital. A $3 million investment made nearly a decade ago has grown into a nearly $100 million stake in a $10.1 billion health-tech powerhouse.
But beyond the financial return, the Whoop story reflects a broader transformation in how Indian corporates engage with the global innovation economy. By backing disruptive platforms early, Infosys has positioned itself at the intersection of technology, health, and AI—sectors that will define the next decade of growth.
As Whoop prepares for its IPO and continues its global expansion, the lesson for Indian corporates is clear: the best venture investments are not just about returns—they are about strategic alignment with the future of technology.
